EPIX vs. FDMT, ETNB, CRON, NUVB, COGT, MESO, DNTH, PLRX, WVE, and PAHC
Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include 4D Molecular Therapeutics (FDMT), 89bio (ETNB), Cronos Group (CRON), Nuvation Bio (NUVB), Cogent Biosciences (COGT), Mesoblast (MESO), Dianthus Therapeutics (DNTH), Pliant Therapeutics (PLRX), Wave Life Sciences (WVE), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.
4D Molecular Therapeutics (NASDAQ:FDMT) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.
4D Molecular Therapeutics has a beta of 2.83, indicating that its share price is 183% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.
4D Molecular Therapeutics' return on equity of -19.46% beat ESSA Pharma's return on equity.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 7.3% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 14.7% of ESSA Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ESSA Pharma received 310 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 76.37% of users gave ESSA Pharma an outperform vote while only 68.42% of users gave 4D Molecular Therapeutics an outperform vote.
ESSA Pharma has lower revenue, but higher earnings than 4D Molecular Therapeutics. ESSA Pharma is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, 4D Molecular Therapeutics had 9 more articles in the media than ESSA Pharma. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 1 mentions for ESSA Pharma. 4D Molecular Therapeutics' average media sentiment score of 1.17 beat ESSA Pharma's score of 0.12 indicating that ESSA Pharma is being referred to more favorably in the news media.
4D Molecular Therapeutics presently has a consensus price target of $43.63, indicating a potential upside of 137.74%. ESSA Pharma has a consensus price target of $16.50, indicating a potential upside of 208.99%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe ESSA Pharma is more favorable than 4D Molecular Therapeutics.
Summary
ESSA Pharma beats 4D Molecular Therapeutics on 9 of the 15 factors compared between the two stocks.
Get ESSA Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ESSA Pharma Competitors List
Related Companies and Tools
